Wision AI Announces Publication of Data from the First-Ever Prospective, Randomized Controlled Trial Evaluating the Use of Artificial Intelligence in Advanced Diagnostics

NEXT STORY
OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRPα antagonist BI 765063* under Development in Collaboration with Boehringer Ingelheim in Patients with Advanced Solid Tumors
PREV STORY
Precision Therapeutics’ Skyline Medical Division Captures Market Share in Saudi Arabia Via New Orders While Disposable Sales Show Significant Year-Over-Year Increase
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

author_avatar
NASDAQ Market News

BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

author_avatar
NASDAQ Market News

Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update

G100 advancing to late-stage development following FDA feedbackConference call at 1:30 pm Pacific todaySEATTLE, ...

author_avatar
NASDAQ Market News